

ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ

ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ

Όνοματεπώνυμο: Ιορδάνης Μουρούζης

Ημερομηνία /τόπος γέννησης : 5 Απριλίου 1976 –ΑΘΗΝΑ

Διεύθυνση Εργασίας : Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Πανεπιστήμιο Αθηνών, Μ. Ασίας 75, 11527 Αθήνα

Τηλ 210- 7462559

email: imour@med.uoa.gr

ΠΑΡΟΥΣΑ ΘΕΣΗ

2016- ΕΠ. ΚΑΘΗΓΗΤΗΣ ΦΑΡΜΑΚΟΛΟΓΙΑΣ - ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΕΚΠΑ

ΕΚΠΑΙΔΕΥΣΗ – ΜΕΤΕΚΠΑΙΔΕΥΣΗ

Προπτυχιακή εκπαίδευση

1994-2001 Ιατρική Σχολή Πανεπιστημίου Αθηνών

Εξειδίκευση

2008- 2012 Ειδικευόμενος Καρδιολογίας ΓΝΑ «ΛΑΪΚΟ»

2004-2006 Ειδικευόμενος Παθολογίας ΓΝΑ «ΕΛΠΙΣ»

Τίτλος Ειδίκευσης

2012- Άδεια ασκήσεως ειδικότητας Καρδιολογίας

Διδακτορική Διατριβή

2006- ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ. «Θυρεοειδική ορμόνη και καρδιοπροστασία: ο ρόλος της πρωτεΐνης θερμικής καταπληξίας 27 (HSP27)», ΕΡΓΑΣΤΗΡΙΟ ΦΑΡΜΑΚΟΛΟΓΙΑΣ, Ιατρική Σχολή Πανεπιστημίου Αθηνών. **ΒΡΑΒΕΙΟ ΚΑΤΣΑΡΑ 2^{ης} καλύτερης διδακτορικής διατριβής για την τριετία 2004-2006**

ΝΟΣΟΚΟΜΕΙΑΚΕΣ ΚΑΙ ΠΑΝΕΠΙΣΤΗΜΙΑΚΕΣ ΘΕΣΕΙΣ

A. Πανεπιστημιακές θέσεις

2014- Λέκτορας Φαρμακολογίας, Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή Πανεπιστημίου Αθηνών

2016- ΕΠ. ΚΑΘΗΓΗΤΗΣ ΦΑΡΜΑΚΟΛΟΓΙΑΣ - ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΕΚΠΑ

B. Νοσοκομειακές θέσεις

2014- Παράλληλη απασχόληση για άσκηση διδακτικού, ερευνητικού και κλινικού έργου στην Γ' Πανεπιστημιακή Καρδιολογική Κλινική, ΕΚΠΑ

2008-2012 Ιατρός ειδικευόμενος στην Καρδιολογία, Καρδιολογική Κλινική, ΓΝΑ «ΛΑΪΚΟ»

2004-2006 Ιατρός ειδικευόμενος στην Παθολογία, Γ' Παθολογική Κλινική, ΓΝΑ «ΕΛΠΙΣ»

2001-2002 Εσωτερικός βοηθός, Παθολογική κλινική, ΓΝΝ Λεβαδείας

ΔΙΔΑΚΤΙΚΟ ΕΡΓΟ

Προπτυχιακή εκπαίδευση

2014- Μαθήματα Καρδιολογίας σε φοιτητές της Ιατρικής, Γ' Πανεπιστημιακή Καρδιολογική Κλινική

2014- Μαθήματα Φαρμακολογίας και φροντιστηριακές ασκήσεις σε φοιτητές της Ιατρικής και Οδοντιατρικής (Πανεπιστήμιο Αθηνών).

Μεταπτυχιακή εκπαίδευση

2014- Μαθήματα στο μεταπτυχιακό πρόγραμμα «ΜΕΘ-Καρδιολογική Νοσηλευτική » (Ιατρική Σχολή, Πανεπιστήμιο Αθηνών)

2014- Μαθήματα στο μεταπτυχιακό πρόγραμμα «ΕΦΑΡΜΟΓΕΣ ΤΗΣ ΒΙΟΛΟΓΙΑΣ ΣΤΗΝ ΙΑΤΡΙΚΗ» (Τμήμα Βιολογίας και Ιατρική Σχολή, Πανεπιστήμιο Αθηνών)

Συμμετοχή στην εκπόνηση διδακτορικών διατριβών στο Εργ. Φαρμακολογίας της Ιατρικής Σχολής

Βιβλία

Συγγραφέας Κεφαλαίων ή/και Συντονιστής Έκδοσης

1. 'Thyroid and heart failure- from pathophysiology to clinics' Iervasi/Pingitore (Eds), Springer, 2008 Chapter by C Pantos, I Mourouzis, DV Cokkinos entitled *Thyroid hormone and ischaemic myocardium*
2. Myocardial ischemia: from mechanisms to therapeutic potentials" Cokkinos/Pantos /Heusch /Taegtmeyer (Eds), Springer, 2006

Επιμέλεια Επιστημονικών μεταφράσεων

Μυοκαρδιακή ισχαιμία: Μηχανισμοί –θεραπευτικές προσεγγίσεις
Cokkinos/Pantos/Heusch/Taegtmeyer (Eds), Springer, 2006, Ελληνική Έκδοση 2006,
Εκδόσεις Παρισιάνος

ΕΡΕΥΝΗΤΙΚΟ ΕΡΓΟ

Περιεχόμενο

- Ο ρόλος της **Θυρεοειδικής ορμόνης στην ιστική επιδιόρθωση** (μυοκάρδιο, νευρικό σύστημα, πάγκρεας, καρκίνος)
- Ανάδειξη του θυρεοειδικού υποδοχέα **α1 (TR α1)** ως **φαρμακολογικού στόχου** για επιδιόρθωση της ιστικής βλάβης
- Μελέτη **ενδογενών μηχανισμών ιστικής επιδιόρθωσης** (repair /regeneration) της μυοκαρδιακής βλάβης (πειραματικά πρότυπα ισχαιμίας/επαναιμάτωσης , εμφράγματος σε μικρά πειραματόζωα, κυτταροκαλιέργειες)
- Ανάδειξη του ρόλου παλαιότερων και νεότερων φαρμακολογικών προσεγγίσεων στην ιστική βλάβη και επιδιόρθωση (**ρανολαζίνη, αμιοδαρόνη, δρονεδαρόνη, τριμεταζιδίνη, δοβουταμίνη, κλενβουτερόλη, φαινυλεφρίνη, σιλδεναφίλη, μορφίνη**).

Άλλα ερευνητικά πεδία

- Computational modeling (διαχείριση και επεξεργασία επιστημονικής πληροφορίας , σχεδιασμός νέων ενδείξεων παλαιών φαρμάκων, modeling φαρμακολογικών στόχων)

Ερευνητικά προγράμματα

“Open semantically-enabled, social-aware access to scientific data” (OPENSOURCELINK), Πρόγραμμα FP7., Φορέας Χρηματοδότησης ΕΕ, Ιδιότητα στο Πρόγραμμα: Συνεργαζόμενο μέλος, (Συντονιστής: TUD, Germany), 2013-2016, **KA 12067**

“Ανάπτυξη καινοτόμων διαγνωστικών και θεραπειών για μυοκαρδιοπάθειες και καρδιακή ανεπάρκεια” με κωδικό 09ΣΥΝ-21-965΄ Φορέας Χρηματοδότησης ΓΓΕΤ. (Συντονιστής: Γ. Καπετανάκη, ΙΙΒΕΑΑ), 2012-2015, **KA 11444**

BIOASQ, Πρόγραμμα FP7. Φορέας Χρηματοδότησης ΕΕ, Ιδιότητα στο Πρόγραμμα Ειδικός επιστήμονας, (Συντονιστής: TUD, Germany), 2013-2014, **KA 4634**

Ο ρόλος της ρανολαζίνης στην καρδιακή αναδιαμόρφωση μετά από έμφραγμα του μυοκαρδίου σε φυσιολογικούς και διαβητικούς επίμους. Ερευνητικά Εργαστήρια Menarini International (Italy) και Gilead Sciences (Fremont, Silicon Valley, USA), (2011-2013), **KA 4634**

“Efficient Patient Recruitment for Innovative Clinical Trials of Existing Drugs to other Indications” (PONTE), Πρόγραμμα FP7, Φορέας Χρηματοδότησης ΕΕ, Ιδιότητα στο Πρόγραμμα Συνεργαζόμενο μέλος, (Συντονιστής: CETIC, Belgium), 2010-2013, **KA 10497**

“Ο ρόλος της θυρεοειδικής ορμόνης στο σχηματισμό βιοτεχνητού καρδιακού μυός (bio-engineered heart muscle) από νεογνικά καρδιακά κύτταρα επίμους.” Ίδρυμα Νιάρχος (2008), **KA 4634**

“Ο ρόλος της θυρεοειδικής ορμόνης στο σχηματισμό βιοτεχνητού καρδιακού μυός (bio-engineered heart muscle) από νεογνικά καρδιακά κύτταρα επίμους.” Ελληνική Καρδιολογική Εταιρεία (2008), **KA 4634**

“Η αναδιαμόρφωση του μυοκαρδίου μετά από έμφραγμα: Πειραματική μελέτη ποικίλων παρεμβάσεων σε καρδιές επιμύων και καρδιομυοκύτταρα.” Ίδρυμα Νιάρχος (2006), **KA 4634**

“Διερεύνηση μηχανισμών καρδιακής αναδιαμόρφωσης μετά από έμφραγμα του μυοκαρδίου”, Ελληνική Καρδιολογική Εταιρεία (2006), **KA 4634**

“Μηχανισμοί δράσης της τριμεταζιδίνης στην ισχαιμία-επαναιμάτωση”, Ερευνητικά Εργαστήρια Servier Γαλλίας, (2002), **KA 4634**

“Ο ρόλος του συστήματος ρενίνης-αγγειοτενσίνης στην προκαλούμενη από θυροξίνη υπερτροφία και η απάντηση της φυσιολογικής και της υπερθυρεοειδικής καρδιάς στην ισχαιμία μετά από χορήγηση ιρμπεζαρτάνης.” Ερευνητικά Εργαστήρια Sanofi-Aventis, Montpellier (2001), **KA 4634**

“Ο ρόλος της αμιωδαρόνης και της δρονεδαρόνης στην απάντηση της φυσιολογικής και της υπερθυρεοειδικής καρδιάς στην ισχαιμία.” Ερευνητικά Εργαστήρια Sanofi-Aventis, Montpellier (1999), **KA 4634**

Πλήρης Κατάλογος Δημοσιεύσεων

1. Eleftheriadou I, Grigoropoulou P, Kokkinos A, Mourouzis I, Perrea D, Katsilambros N, Sfrikakis P, Tentolouris N Association of plasma fetuin-A levels with peripheral arterial disease and lower extremity arterial calcification in subjects with type 2 diabetes mellitus *Journal of Diabetes and Its Complications* 2016 (in press)
2. Pantos C., Mourouzis I. "Thyroid hormone and tissue repair" *Thyroid International* 2016-1
3. Mourouzis I, Tzovaras A, Armonis B, Ardavanis A, Skondra M, Misitzis J, Pectasides D, Pantos C. Are Thyroid Hormone and Tumor Cell Proliferation in Human Breast Cancers Positive for HER2 Associated? *Int J Endocrinol.* 2015;2015:765406.
4. Pantos C, Mourouzis I. Translating thyroid hormone effects into clinical practice: the relevance of thyroid hormone receptor $\alpha 1$ in cardiac repair. *Heart Fail Rev.* 2015 May;20(3):273-82.
5. Mourouzis I, Pantos C. The Biomedical Data Journal in the New Era of Open Access to Scientific Information *Biomed Data J.* 2015; 1(1): 5-11
6. Angelopoulos T, Kokkinos A, Liaskos C, Tentolouris N, Alexiadou K, Miras AD, Mourouzis I, Perrea D, Pantos C, Katsilambros N, Bloom SR, le Roux CW. The effect of slow spaced eating on hunger and satiety in overweight and obese patients with type 2 diabetes mellitus. *BMJ Open Diabetes Res Care.* 2014 Jul 2;2(1):e000013.
7. Mourouzis I, Saranteas T, Ligeret H, Portal C, Perimenis P, Pantos C. Phenylephrine postconditioning increases myocardial injury: are alpha-1 sympathomimetic agonist cardioprotective? *Ann Card Anaesth.* 2014 Jul-Sep;17(3):200-9.
8. Pantos C, Mourouzis I. The vulnerable myocardium: need for a paradigm shift for the management of coronary artery disease? *Cardiology.* 2014;129(1):18-9.
9. Mourouzis I, Mantzouratou P, Galanopoulos G, Kostakou E, Dhalla AK, Belardinelli L, Pantos C. The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than non-diabetic rats *Journal of Cardiovascular Pharmacology and Therapeutics.* 2014 Sep;19(5):457-69.
10. Pantos C, Mourouzis I. The emerging role of TR $\alpha 1$ in cardiac repair: potential therapeutic implications. *Oxidative Medicine and Cellular Longevity* 2014;2014:481482
11. Lourbopoulos A, Mourouzis I*, Karapanayiotides T, Nousiopolou E, Chatzigeorgiou S, Mavridis T, Kokkinakis I, Touloumi O, Irinopolou T, Chouliaras K, Pantos C, Karacostas D, Grigoriadis N. Changes in thyroid hormone receptors after permanent cerebral ischemia in male rats. *J Mol Neurosci.* 2014 Sep;54(1):78-91.

12. Mourouzis I, Giagourta I, Galanopoulos G, Mantzouratou P, Kostakou E, Kokkinos AD, Tentolouris N, Pantos C. Thyroid hormone improves the mechanical performance of the post-infarcted diabetic myocardium: A response associated with up-regulation of Akt/mTOR and AMPK activation. *Metabolism* 2013;62:1387-1393
13. Strilakou, A.A., Tsakiris, S.T., Kalafatakis, K.G., Stylianaki, A.T., Karkalousos, P.L., Koulouris, A.V., Mourouzis, I.S., Liapi, C.A. Carnitine modulates crucial myocardial adenosine triphosphatases and acetylcholinesterase enzyme activities in choline-deprived rats. *Canadian Journal of Physiology and Pharmacology*, 2014; 92 (1): 78-84.
14. Adamopoulos, S., Gouziouta, A., Mantzouratou, P., Laoutaris, I.D., Dritsas, A., Cokkinos, D.V., Mourouzis, I., Sfyraakis, P., Iervasi, G., Pantos, C. Thyroid hormone signalling is altered in response to physical training in patients with end-stage heart failure and mechanical assist devices: Potential physiological consequences? *Interactive Cardiovascular and Thoracic Surgery*, 2013 Oct;17(4):664-8..
15. Mourouzis, I., Kostakou, E., Galanopoulos, G., Mantzouratou, P., Pantos, C. Inhibition of thyroid hormone receptor $\alpha 1$ impairs post-ischemic cardiac performance after myocardial infarction in mice. *Molecular and Cellular Biochemistry*, 2013 Jul;379(1-2):97-105.
16. Strilakou, A.A., Lazaris, A.C., Perelas, A.I., Mourouzis, I.S., Douzis, I.C., Karkalousos, P.L., Stylianaki, A.T., Pantos, C.I., Liapi, C.A. Heart dysfunction induced by choline-deficiency in adult rats: The protective role of l-carnitine. *European Journal of Pharmacology*, 2013 Jun 5;709(1-3):20-7.
17. Vilaeti, A.D., Dimos, K., Lampri, E.S., Mantzouratou, P., Tsitou, N., Mourouzis, I., Oikonomidis, D.L., Papalois, A., Pantos, C., Malamou-Mitsi, V., Agathopoulos, S., Kolettis, T.M. Short-term ventricular restraint attenuates post-infarction remodeling in rats. *International Journal of Cardiology*, 2013 May 10;165(2):278-84.
18. Papadopoulos, D.P., Mourouzis, I., Faselis, C., Perrea, D., Makris, T., Tsioufis, C., Papademetriou, V. Masked Hypertension and Atherogenesis: The Impact of Apelin and Relaxin Plasma Levels. *Journal of Clinical Hypertension*, 2013;15 (5): 333-336.
19. Mourouzis, I., Politi, E., Pantos, C. Thyroid hormone and tissue repair: New tricks for an old hormone? *Journal of Thyroid Research*, 2013;2013:312104.
20. Galanakis, S.P., Zoubos, A.B., Mourouzis, I., Ignatiadis, I., Bot, A.G.J., Soucacos, P.N. Prognostic scoring system for peripheral nerve repair in the upper extremity. *Microsurgery*, 2013;33 (2):105-111.
21. Spanou D, Perimenis P, Mantzouratou P, Gomatos C, Cokkinos D, Mourouzis I, Pantos C. Clenbuterol favorably remodels neonatal cardiac cells via activation of p38 MAPK signalling pathway. *J Cardiovasc Surg (Torino)*. 2012 Dec;53(6):789-95
22. Pantos C, Mourouzis I, Cokkinos DV. Thyroid hormone and cardiac repair/regeneration: from Prometheus myth to reality? *Can J Physiol Pharmacol*. 2012 Aug;90(8):977-87
23. Mourouzis I, Mantzouratou P, Galanopoulos G, Kostakou E, Roukounakis N, Kokkinos AD, Cokkinos DV, Pantos C. Dose-dependent effects of thyroid hormone on post-ischemic cardiac performance: potential involvement of Akt and ERK

signalings. *Mol Cell Biochem.* 2012 Apr;363(1-2):235-43

24. Papadopoulos DP, Mourouzis I, Thomopoulos C, Makris T, Papademetriou V. Hypertension crisis. *Blood Press.* 2010 Dec;19(6):328-36.
25. Papadopoulos, D., Mourouzis, I., Kotrotsou, A., Papazachou, U., Sanidas, E., Tsioufis, K., Makris, T. Hemostasis parameters disturbances in healthy individuals with prehypertension (2012) *Clinical and Experimental Hypertension*, 34 (6), pp. 385-388.
26. Mourouzis I, Forini F, Pantos C, Iervasi G. Thyroid hormone and cardiac disease: from basic concepts to clinical application. *J Thyroid Res.* 2011;2011:958626.
27. Pantos C, Mourouzis I, Cokkinos DV. New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider? *Heart Fail Rev.* 2011 Jan;16(1):79-96.
28. Liappas A, Mourouzis I, Zisakis A, Economou K, Lea RW, Pantos C. Cell-type-dependent thyroid hormone effects on glioma tumor cell lines. *J Thyroid Res.* 2011;2011:856050.
29. Lymvaivos I, Mourouzis I, Cokkinos DV, Dimopoulos MA, Toumanidis ST, Pantos C. Thyroid hormone and recovery of cardiac function in patients with acute myocardial infarction: a strong association? *Eur J Endocrinol.* 2011 Jul;165(1):107-14.
30. Pantos C, Mourouzis I, Saranteas T, Brozou V, Galanopoulos G, Kostopanagiotou G, Cokkinos DV. Acute T3 treatment protects the heart against ischemia-reperfusion injury via TR α 1 receptor. *Mol Cell Biochem.* 2011 Jul;353(1-2):235-41
31. Tigka, E., Saranteas, T., Mourouzis, I., Kotsiou, A. The influence of clonidine co-administration on the extent of lidocaine protein binding to rat serum and tissues. (2011) *Journal of oral science*, 53 (1), pp. 61-66.
32. Papadopoulos, D.P., Thomopoulos, C., Mourouzis, I., Kotrotsou, A., Sanidas, E., Papazachou, U., Daskalaki, M., Makris, T.K. Masked hypertension unfavourably affects haemostasis parameters (2011) *Blood Pressure*, 20 (4), pp. 218-221.
33. Pantos, C., Mourouzis, I. Comment: Worsening heart failure in the setting of dronedarone initiation (2011) *Annals of Pharmacotherapy*, 45 (5), p. 690.
34. Pantos C, Mourouzis I, Cokkinos DV. Thyroid hormone as a therapeutic option for treating ischaemic heart disease: from early reperfusion to late remodelling. *Vascul Pharmacol.* 2010 Mar-Apr;52(3-4):157-65.
35. Pantos C, Mourouzis I, Cokkinos DV. Rebuilding the post-infarcted myocardium by activating 'physiologic' hypertrophic signaling pathways: the thyroid hormone paradigm. *Heart Fail Rev.* 2010 Mar;15(2):143-54.
36. Kalofoutis C, Mourouzis I, Galanopoulos G, Dimopoulos A, Perimenis P, Spanou D, Cokkinos DV, Singh J, Pantos C. Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction. *Mol Cell Biochem.* 2010 Dec;345(1-2):161-9.
37. Pantos C, Mourouzis I, Galanopoulos G, Gavra M, Perimenis P, Spanou D, Cokkinos DV. Thyroid hormone receptor alpha1 downregulation in postischemic heart failure progression: the potential role of tissue hypothyroidism. *Horm Metab Res.* 2010

Sep;42(10):718-24.

38. Papadopoulos, D.P., Mourouzis, I., Votteas, V., Papademetriou, V. Depression masked as paroxysmal hypertension episodes (2010) *Blood Pressure*, 19 (1), pp. 16-19.
39. Kolettis TM, Kontaras K, Spartinos I, Maniotis C, Varnavas V, Koutouzis M, Mourouzis I, Papalois A, Pantos C, Kyriakides ZS. Dose-dependent effects of sildenafil on post-ischaemic left ventricular function in the rat isolated heart. *J Pharm Pharmacol*. 2010 Mar;62(3):346-51
40. Kostopanagiotou, G., Kalimeris, K., Christodoulaki, K., Nastos, C., Papoutsidakis, N., Dima, C., Chrelias, C., Pandazi, A., Mourouzis, I., Pantos, C. The differential impact of volatile and intravenous anaesthetics on stress response in the swine (2010) *Hormones*, 9 (1), pp. 67-75.
41. Pantos C, Mourouzis I, Tsagoulis N, Markakis K, Galanopoulos G, Roukounakis N, Perimenis P, Liappas A, Cokkinos DV. Thyroid hormone at supra-physiological dose optimizes cardiac geometry and improves cardiac function in rats with old myocardial infarction. *J Physiol Pharmacol*. 2009 Sep;60(3):49-56.
42. Papakostas I, Mourouzis I, Mourouzis K, Macheras G, Boviatsis E, Pantos C. Functional effects of local thyroid hormone administration after sciatic nerve injury in rats. *Microsurgery*. 2009;29(1):35-41.
43. Mourouzis I, Saranteas T, Perimenis P, Tesseromatis C, Kostopanagiotou G, Pantos C, Cokkinos DV Morphine administration at reperfusion fails to improve postischemic cardiac function but limits myocardial injury via increased phosphorylation of HSP27 *Eur J Anesthesiol* 2009; 26 (7): 572-581
44. Pantos C, Mourouzis I, Saranteas T, Clavé G, Ligeret H, Noack-Fraissignes P, Renard P, Massonneau M, Perimenis P, Spanou D, Kostopanagiotou G, Cokkinos DV. Thyroid hormone improves postischaemic recovery of function while limits apoptosis: a new therapeutic approach to support haemodynamics in the setting of ischaemia-reperfusion? *Basic Res Cardiol*, 2009 Jan;104(1):69-77.
45. Mourouzis I, Dimopoulos A, Saranteas T, Tsinarakis N, Livadarou E, Spanou D, Kokkinos AD, Xinaris C, Pantos C, Cokkinos DV. Ischaemic preconditioning fails to confer additional protection against ischaemia –reperfusion injury in the hypothyroid rat heart. *Physiol Res*, 2009, 58 (1): 29-38
46. Pappas, M., Mourouzis, K., Karageorgiou, H., Tesseromatis, C., Mourouzis, I., Kostopanagiotou, G., Pantos, C., Cokkinos, D.V. Thyroid hormone modulates the responsiveness of rat aorta to α 1-adrenergic stimulation: An effect due to increased activation of β 2-adrenergic signaling (2009) *International Angiology*, 28 (6), pp. 474-478.
47. Kostopanagiotou, G., Kalimeris, K., Mourouzis, I., Costopanagiotou, C., Arkadopoulos, N., Panagopoulos, D., Papoutsidakis, N., Chranioti, A., Pafiti, A., Spanou, D., Smyrniotis, V., Pantos, C. Thyroid hormones alterations during acute liver failure: Possible underlying mechanisms and consequences (2009) *Endocrine*, 36 (2), pp. 198-204.
48. Xinaris Ch, Mourouzis I, Perimenis P, Politi E, Spanou D, Cokkinos DV. TR alpha1 : a switch to cardiac cell metamorphosis? *J Physiol Pharmacol*, 2008 , 59:253-69

49. Pantos C, Mourouzis I, Markakis K, Tsagoulis N, Kokkinos AD, Panagiotou M, Cokkinos DV. Long-term thyroid hormone administration re-shapes left ventricular chamber and improves cardiac function after myocardial infarction in rats. *Basic Res Cardiol*, 2008, 103:308-18
50. Pantos C, Mourouzis I, Xinaris Ch, Z Daifoti-Papadopoulou, Cokkinos DV. Thyroid hormone and «cardiac metamorphosis»: potential therapeutic implications. *Pharmacol Ther*, 2008, 59:253-69.
51. Pantos C, Xinaris Ch, Mourouzis I, Kokkinos AD, Cokkinos DV. TNF- α administration in neonatal cardiomyocytes is associated with differential expression of thyroid hormone receptors : a response prevented by T3. *Horm Metab Res*, 2008, 40:731-4
52. Pantos C, Mourouzis I, Xinaris Ch, Cokkinos DV. Thyroid hormone and myocardial ischaemia. *J Steroid Biochem Mol Biol*, 2008, 109: 314-322
53. Halapas A, Lembessis P, Mourouzis I, Pantos C, Cokkinos D, Sourla A, Koutsilieris M. Experimental hyperthyroidism increases the level of PTHrP/PTH.1R expression in rat ventricular myocardium of Langendorff's ischaemia/ reperfusion model. *Exp Physiol*, 2008, 93:237-46.
54. Kokkinos A, Mourouzis I, Kyriaki D, Pantos C, Katsilambros N, Cokkinos DV. Possible implications of leptin, adiponectin and ghrelin in the regulation of energy homeostasis by thyroid hormone. *Endocrine* 2007; 32(1):30-2.
55. Carageorgiou H, Pantos C, Zarros A, Stolakis V, Mourouzis I, Cokkinos D, Tsakiris S Changes in acetylcholinesterase Na,K-ATPase and Mg-ATPase activities in the frontal cortex and the hippocampus of hyper- and hypothyroid adult rats. *Metabolism*, 2007, 56, 1104-10.
56. Saranteas T, Tachmitzis A, Katsikeris N, Lykoudis E, Mourouzis I, Anteriotis D, Alexopoulos C, Dimakopoulou A, Dimitriou V, Pantos C, Tesserommatis C. Perioperative thyroid hormone kinetics in patients undergoing major oral and maxillofacial operations *J Oral Maxillofac Surg* 2007, 65:408-414
57. Tzotzes V, Tzilalis V, Giannakakis S, Saranteas T, Papas A, Mourouzis I, Mourouzis C, Zarros A, Pantos C, Cokkinos DV, Carageorgiou H. Effects of acute and chronic cadmium administration on the vascular reactivity of rat aorta. *Biometals* , 2007, 20: 83-91.
58. Carageorgiou H, Pantos C, Zarros A, Stolakis V, Mourouzis I, Cokkinos D, Tsakiris S. Effects of hyper- and hypothyroidism on acetylcholinesterase, (Na(+), K (+))- and Mg (2+)-ATPase activities of adult rat hypothalamus and cerebellum. *Metabolic Brain Dis* 2007;22:31-38
59. Pantos C, Mourouzis I, Cokkinos DV. Abnormal heart and cardioprotection. *Heart Failure Rev* 2007, 12, 319-330. Invited review.
60. Pantos C, Mourouzis I, Dimopoulos A, Markakis K, Panagiotou M, Xinaris C, Tzeis S, Kokkinos AD, Cokkinos DV. Enhanced tolerance of the rat myocardium to ischemia and reperfusion injury early after acute myocardial infarction. *Basic Res Cardiol* 2007 ;102: 327-333

61. Pantos C, Mourouzis I, Paizis V, Malliopoulos V, Xinaris C, Moraitis P, Cokkinos DV. Pharmacological inhibition of TR α 1 receptor potentiates the thyroxine effect on body weight reduction: potential therapeutic implications in controlling body weight. *Diabetes Obesity & Metabolism*. 2007, 9:136-138
62. Kolettis TM, Agelaki MG, Baltogiannis GG, Vlahos AP, Mourouzis I, Fotopoulos A, Pantos C. Comparative effects of acute vs chronic oral amiodarone treatment during acute myocardial infarction in rats. *Europace* 2007, (9): 1099-1104.
63. Pantos C, Dritsas A, Mourouzis I, Dimopoulos A, Kratasakis G, Athanassopoulos G, Mavrogeni S, Manginas A, Cokkinos DV. Thyroid hormone is a critical determinant of myocardial performance in patients with heart failure: potential therapeutic implications. *Eur J Endocrinol*, 2007, 157:515-20.
64. Pantos C, Mourouzis I, Xinaris Ch, Cokkinos A D, Markakis K, Dimopoulos A, Panagiotou M, Saranteas TH, Kostopanagiotou G, Cokkinos DV. Time dependent changes in the expression of TR α 1 in the myocardium after acute myocardial infarction: possible implications for cardiac remodeling *Eur J Endocrinol*, 2007, 156:415-424
65. Pantos C, Mourouzis I, Markakis K, Dimopoulos A, Xinaris C, Cokkinos AD, Panagiotou M, Cokkinos DV. Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats. *Eur J Cardiothorac Surg*, 2007, 32: 333-9.
66. Pantos C, Xinaris Ch, Mourouzis I, Malliopoulos V, Kardami E, Cokkinos DV. Thyroid hormone changes cardiomyocyte shape and geometry via ERK signaling pathway: potential therapeutic implications in reversing cardiac remodeling? *Mol Cell Biochem*, 2007, 297:65-72.
67. Pantos C, Mourouzis K, Katramadou M, Saranteas T, Mourouzis I, Karageorgiou H, Tesseromatis CH, Kostopanagiotou G, Asimacopoulos P, Cokkinos DV. Decreased vascular reactivity to α 1 adrenergic stimulation in the presence of hypothyroid state: a part of an adaptive response? *Int. Angiology* , 2006, 25(2):216-20.
68. Malliopoulos V, Xinaris Ch, Mourouzis I, Cokkinos A, Katsilambros N, Pantos C, Kardami E, Cokkinos DV. High glucose protects embryonic cardiac cells against simulated ischaemia. *Mol Cell Biochem*, 2006 ; 284(1-2):87-93.
69. Pantos C, Malliopoulos V, Mourouzis I, Thempeyioti A, Paizis I, Dimopoulos A, Saranteas T, Xinaris Ch, Cokkinos DV. Hyperthyroid hearts display a phenotype of cardioprotection against ischemic stress: a possible involvement of heat shock protein 70. *Horm Metab Res* , 2006, 38:1-6.
70. Pantos C, Bescond-Jacquet A, Tzeis S, Paizis I, Mourouzis I, Moraitis P, Malliopoulos V, Politi ED, Karageorgiou H, Varonos D, Cokkinos DV. Trimetazidine protects isolated rat hearts against ischemia-reperfusion injury in an experimental timing- dependent manner *Bas Res Cardiol*, 2005, 100; 154-160.
71. Carageorgiou H, Pantos C, Zarros A, Mourouzis I, Varonos D, Cokkinos D, Tsakiris S. Changes in antioxidant status, protein concentration, acetylcholinesterase, Na,K-ATPase and Mg-ATPase activities in the brain of hyper- and hypothyroid adult rats.

Metab Brain Dis, 2005, 20:129-139.

72. Pantos C, Mourouzis I, Malliopoulou V, Paizis I, Tzeis S, Moraitis P, Sfakianoudis K, Varonos D, Cokkinos DV Dronedarone administration prevents body weight gain and increases tolerance of the heart to ischaemic stress: a possible involvement of thyroid hormone nuclear receptor α 1 blockade. *Thyroid* 2005, 15: 16-23.
73. Pantos C, Mourouzis I, Saranteas T, Paizis I, Xinaris C, Malliopoulou V, Cokkinos DV. Thyroid hormone receptors α 1 and β 1 are downregulated in the post-infarcted rat heart: consequences on the response to ischemia-reperfusion. *Basic Res Cardiol.* 2005;100(5): 422-432.
74. Pantos C, Paizis I, Mourouzis I, Moraitis P, Tzeis S, Karamanoli E, Mourouzis C, Karageorgiou H, Cokkinos DV. Blockade of angiotensin II type 1 receptor diminishes cardiac hypertrophy, but does not abolish thyroxine-induced preconditioning. *Horm Metab Res*, 2005; 37(8): 500-504.
75. Mourouzis C, Pantos C, Mourouzis I, Saranteas T, Tesseromatis C, Kostopanagiotou G, Karageorgiou C, Varonos D, Cokkinos DV Mepivacaine alters vascular responsiveness to vasoconstrictors in aortic rings from normal and aortic banded rats. *Pharmacol Toxicol*, 2003, 93 ;269-274
76. Pantos C, Malliopoulou V, Mourouzis I, Moraitis P, Tzeis S, Thempeyioti A, Paizis I, Cokkinos AD, Carageorgiou H, Varonos D, Cokkinos DV Involvement of p38 MAPK and JNK in the heat stress induced cardioprotection. *Bas Res Cardiol*, 2003, 98: 158-164
77. Pantos C, Malliopoulou V, Mourouzis I, Sfakianoudis K, Tzeis S, Doumba P, Xinaris Ch, Cokkinos AD, Carageorgiou H, Varonos D, Cokkinos DV Propylthiouracil induced hypothyroidism is associated with increased tolerance of the isolated rat heart to ischaemia-reperfusion. *J Endocrinol*, 2003, 178(3) :427-435
78. Pantos C, Malliopoulou V, Mourouzis I, Karamanoli E, Moraitis P, Tzeis S, Paizis I, Carageorgiou H, Varonos D, Cokkinos DV Thyroxine pretreatment increases basal myocardial HSP27 expression and accelerates translocation and phosphorylation of this protein upon ischaemia. *Eur J Pharmacol*, 2003, 478; 53-60.
79. Pantos C, Mourouzis I, Tzeis S, Moraitis P, Malliopoulou V, Cokkinos DD, Carageorgiou H, Varonos D, Cokkinos DV Dobutamine administration exacerbates postischaemic myocardial dysfunction in isolated rat hearts; An effect reversed by thyroxine pre-treatment. *Eur J Pharmacol*, 2003, 460: 155-161
80. Pantos C, Malliopoulou V, Paizis I, Moraitis P, Mourouzis I, Tzeis S, Karamanoli E, Cokkinos DD, Carageorgiou H, Varonos D, Cokkinos DV Thyroid hormone and cardioprotection; study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart. *Mol Cell Biochem*, 2003, 242: 173-180
81. Pantos C, Mourouzis I, Delbruyere M, Malliopoulou V, Tzeis S, Cokkinos DD, Nikitas N, Carageorgiou H, Varonos D, Cokkinos DV, Nisato D Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischaemic performance of the isolated rat heart. *Eur J Pharmacol*, 2002, 444: 191-196
82. Pantos C, Malliopoulou V, Mourouzis I, Karamanoli E, Paizis I, Steimberg N, Varonos D, Cokkinos DV Long-term Thyroxine Administration Protects the Heart in

a Similar Pattern as Ischaemic Preconditioning. *Thyroid*, 2002, 12: 325-329

83. Pantos C, Malliopoulos V, Mourouzis I, Karamanoli E, Tzeis SM, Carageorgiou H, Varonos D, Cokkinos DV Long-term thyroxine administration increases HSP70 mRNA expression and attenuates p38 MAP kinase activity in response to ischaemia. *J Endocrinol*, 2001, 170: 207-215
84. Pantos C, Tzilalis V, Giannakakis S, Cokkinos DD, Tzeis SM, Malliopoulos V, Mourouzis I, Asimacopoulos P, Carageorgiou H, Varonos DD, Cokkinos DV (2001) Phenylephrine induced aortic vasoconstriction is attenuated in hyperthyroid rats. *Int Angiol*, 2001, 20: 181-186
85. Pantos C, Mourouzis I, Tzeis S, Malliopoulos V, Cokkinos DD, Asimakopoulos P, Carageorgiou H, Varonos DD, Cokkinos DV Propranolol diminishes cardiac hypertrophy but does not abolish acceleration of the ischaemic contracture in hyperthyroid hearts. *J Cardiovasc Pharmacol*, 2000, 36: 384-389
86. Pantos C, Cokkinos DD, Tzeis S, Malliopoulos V, Mourouzis I, Carageorgiou H, Limas C, Varonos D, Cokkinos DV Hyperthyroidism is associated with preserved preconditioning capacity but intensified and accelerated ischaemic contracture in rat heart. *Basic Res Cardiol*, 1999, 94: 254-260

Κατάλογος περιλήψεων σε διεθνή συνέδρια/επιστημονικές συναντήσεις

1. Mourouzis I, Mantzouratou P., Galanopoulos G., Kostakou E., Dhalla A.K., Belardinelli L., Pantos C. “*The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than non-diabetic rats*” 6th Annual Meeting, Diabetes and Cardiovascular Disease Study Group, October 31-Nov 2, Prague, Czech Republic
2. Adamopoulos S, Cokkinos DV, Gouziouta A, Mantzouratou P, Kostakou E, Laoutaris ID, Dritsas A, Mourouzis I, Sfyraakis P, Iervasi G, Pantos C. Exercise Training Up-Regulates Physiological Growth Signalling in the Myocardium of Patients with Mechanical Circulatory Support: Relevance to Functional Recovery. 62nd Annual Scientific Sessions ACC, Journal of the American College of Cardiology 2013, Vol. 61, Issue 10, Supplement, Page E666.
3. Cokkinos DV, Arvanitis D, Mourouzis I, Pantos C, Kranias EG, Sanoudou D Sarcoplasmic reticulum calcium uptake changes and cell survival after experimental acute myocardial infarction. 61 Annual Scientific Sessions ACC, Journal of the American College of Cardiology 27 March 2012 (Vol. 59, Issue 13, Page E451)
4. Mourouzis I, Perimenis F, Spanou D, Markakis K, Tsagoulis N, Kokkinos AD, Pantos C, DV Cokkinos. Changes in thyroid hormone signalling may contribute to cardiac fetal phenotype after myocardial infarction in rats. *J Mol Cell Cardiol* 2008, 44, 73
5. Mourouzis I, Dritsas A, Dimopoulos A, Karatasakis G, Athanasopoulos G, Manginas A, Pantos C, DV Cokkinos. Thyroid hormone is an independent determinant of myocardial oxygen consumption in patients with heart failure. *J Mol Cell Cardiol* 2008, 44, 72
6. Mourouzis I, Xinaris C, Markakis K, Tzeis S, Paizis I, Moraitis P, Pantos C, Cokkinos DV. HSP 70 is down regulated at late stages after myocardial infarction in rats ; a response reversed by thyroid hormone . *J Mol Cell Cardiol* 2007, S212.
7. Kokkinos A, Dimopoulos A, Tsinarakis N, Mourouzis I, Karageorgiou H, Pantos C, Cokkinos DV. Ischaemic preconditioning blunts the postischaemic response of the hypothyroid rat heart. *J Mol Cell Cardiol* 2007, 42: S175.

8. Mourouzis I, Markakis K, Dimopoulos A, Xinaris C, Panagiotou M, Pantos C, Cokkinos DV. Thyroid hormone attenuates cardiac remodelling and improves haemodynamics early after myocardial infarction. *Eur Heart J* 2007, P3934.
9. Xinaris C, Mourouzis I, Livadarou E, Perimenis P, Spanou D, Pantos C, Cokkinos DV. Negative regulation of TR β 1 receptor by TNF α administration in neonatal cardiac cells: an effect reversed by T3. *Eur Heart Journal* 2007, P2174.
10. Xinaris C, Mourouzis I, Pantos C, Cokkinos DV. Thyroid hormone promotes cardiac myocyte plasticity via activation of stress kinase signaling. *J Mol Cell Cardiol* 2006, 40:999-1000.
11. Xinaris C, Mourouzis I, Carageorgiou H, Pantos C, Cokkinos DV. Differential activation of stress kinase signaling by phenylephrine and thyroid hormone in neonatal cardiomyocytes. *J Mol Cell Cardiol* 2006, 40: 999.
12. Mourouzis I, Markakis K, Saranteas T, Dimopoulos A, Tzeis S, Panagiotou M, Pantos C, Cokkinos DV. Changes in thyroid hormone signaling contributes to fetal programming after myocardial infarction in rats. *J Mol Cell Cardiol* 2006, 40:940.
13. Carageorgiou H, Pantos C, Zarros A, Stolakis V, Mourouzis I, Cokkinos D, Tsakiris S. Effects of hyper-hypothyroidism on enzyme activities of rat brain regions. *FEBS J* 2006, 273: PP856.(7.16)
14. Xinaris C, Mourouzis I, Pantos C, Cokkinos DV. Thyroid hormone remodels cardiac myocytes via activation of stress kinase signalling. *Eur Heart J* 2006, 27:554
15. Pantos C, Malliopoulou V, Mourouzis I, Thempeyioti A, Paizis I, Xinaris C, Dimopoulos A, Cokkinos DD, Cokkinos DV. Thyroid hormone protects the heart against ischaemia-reperfusion injury through a redox regulated survival signaling. *JACC*, 2006, 47(4) : 180A.
16. Pantos C, Mourouzis I, Saranteas T, Charitsis G, Paizis I, Tesseromatis C, Cokkinos DV. Thyroid hormone receptors α 1 and β 1 are downregulated in the post-infarcted rat heart: consequences on the response to ischaemia-reperfusion. *JACC*, 2006, 47(4) : 179A-180A.
17. Malliopoulou V, Xinaris C, Mourouzis I, Kardami E, Pantos C, Cokkinos DV. High glucose protects embryonic cardiac myocytes against simulated ischemia. *J Mol Cell Cardiol* 2005; 38:1052
18. Pantos C, Mourouzis I, Saranteas T, Haritsis G, Paizis I, Tesseromatis C, DV Cokkinos. Post infarcted myocardium is more tolerant to ischemia-reperfusion injury *J Mol Cell Cardiol* 2005; 38:1053
19. Mourouzis I, Cokkinos AD, Moraitis P, Tzeis S, Paizis I, Malliopoulou V, Pantos C, DV Cokkinos. Hyperthyroid heart displays a phenotype of increased tolerance to ischemia-reperfusion injury. *J Mol Cell Cardiol* 2005; 38:1054
20. Pantos C, Mourouzis I, Sfakianoudis K, Tzeis S, Cokkinos AD, Moraitis P, Paizis I, Malliopoulou V, DV Cokkinos. Dronedarone increases tolerance of the heart to ischaemia-reperfusion; evidence of possible involvement of TR α 1. *J Mol Cell Cardiol* 2005; 38:1054
21. Pantos, C; Mourouzis, I; Paizis, I; Cokkinos, AD; Katsilambros, N; Cokkinos, DV Blockade of thyroid hormone receptor alpha 1 suppresses food intake and potentiates thyroxine effect on body weight reduction *Eur Heart J* 26: 608-608 Suppl. 1 SEP 2005
22. Malliopoulou, V; Cokkinos, AD; Thempeyioti, A; Mourouzis, I; Pantos, C; Cokkinos, DV Thyroxine administration increases the expression of HSP27 and HSP70 and protects the heart against ischaemia-reperfusion injury *Eur Heart J* 2005, 26: 608-608 Suppl.
23. Pantos, C; Mourouzis, I; Paizis, I; Tzeis, S; Moraitis, P; Sfakianoudis, K; Varonos, D; Cokkinos, DV Blockade of thyroid hormone nuclear receptor alpha1 by dronedarone increases the tolerance of the isolated rat heart to ischaemia-reperfusion injury. *Eur Heart J* 2005, 25: 339-339 Suppl. S
24. Saranteas T, Mourouzis C, Mourouzis I, Tesseromatis C, Kostopanagiotou G, Pantos C, Karageorgiou C, Varonos D, Cokkinos DV. Effect of mepivacaine on the EC50 to

- phenylephrine in aortic rings from normal and aortic banded rats. NAUNYN-SCMIEDEBERGS ARCHIEVES OF PHARMACOLOGY, 2003, 367:105.
25. Pantos C, Malliopoulou V, Mourouzis I, Karamanoli E, Moraitis P, Tzeis S, Varonos D, Cokkinos DV. Hypothyroid rat hearts display increased tolerance to ischaemia reperfusion ; investigation of possible mechanisms. *Eur Heart J* 2003 ; 24:477.
 26. Malliopoulou V, Pantos C, Mourouzis I, Tzeis S, Karamanoli E, Cokkinos A, Varonos D, Cokkinos DV. Ischaemic preconditioning potentiates thyroxine induced cardioprotection: a possible association to attenuated p38 MAPK activation during ischaemia. *J Mol Cell Cardiol* 2002; 34: A41.
 27. Paizis I, Malliopoulou V, Mourouzis I, Tzeis S, Cokkinos DD, Pantos C, Varonos D, Cokkinos DV. Involvement of p38MAPK in ischaemic preconditioning and thyroxine induced cardioprotection. *Eur Heart J* 2002; 23:294.
 28. Moraitis P, Paizis I, Malliopoulou V, Mourouzis I, Tzeis S, Cokkinos DD, Pantos C, Varonos D, Cokkinos DV. Ischaemic preconditioning potentiates heat stress induced cardioprotection. *J Mol Cell Cardiol* 2002;34:A44.
 29. Moraitis P, Malliopoulou V, Paizis I, Tzeis S, Mourouzis I, Cokkinos DD, Pantos C, Varonos D, Cokkinos DV. Ischaemic preconditioning and reperfusion: study of the activation pattern of p38 MAPK and JNK. *J Mol Cell Cardiol* 2002;34:A44
 30. Pantos C, Malliopoulou V, Tzeis S, Paizis I, Mourouzis I, Cokkinos DD, Varonos D, Cokkinos DV. Long term thyroxine administration protects the heart in a similar pattern as ischaemic preconditioning. *J Mol Cell Cardiol* 2002; 34:A48
 31. Pantos C, Malliopoulou V, Mourouzis I, Cokkinos AD, Paizis I, Moraitis P, Varonos D, Cokkinos DV. Thyroid hormone and cardioprotection : study of p38 MAPK and JNK activation pattern during ischaemia and reperfusion. *J Mol Cell Cardiol* 2002; 34:A48.
 32. Pantos C, Malliopoulou V, Tzeis S, Paizis I, Mourouzis I, Cokkinos DD, Varonos D, Cokkinos DV. Heat stress and ischaemic preconditioning produce similar patterns as regards p38 MAPK and JNKs activation in the isolated rat heart. *Eur Heart J* 2002; 23:206.
 33. Mourouzis I, Pantos C, Malliopoulou V, Tzeis S, Cokkinos AD, Karamanoli E, Varonos D, Cokkinos DV. Thyroxine administration decreases p38 MAPK activation in response to ischaemia and increases postischaemic recovery of function in the isolated rat heart. *Eur Heart J* 2001; P398
 34. Malliopoulou V, Pantos C, Mourouzis I, Paizis I, Moraitis P, Cokkinos AD, Varonos D, Cokkinos DV. Ischaemic preconditioning increases p38 MAPK activation in a dose response fashion. *Eur Heart J* 2001;P3687
 35. Pantos C, Malliopoulou V, Karamanoli E, Tzeis S, Mourouzis I, Cokkinos DD, Varonos D, Cokkinos DV. Enhanced tolerance to ischaemia of thyroxine treated rat heart in associated with attenuated p38 MAPK activation. *J Mol Cell Cardiol* 2001,33:A 89
 36. Pantos C, Mourouzis I, Malliopoulou V, Karamanoli E, Cokkinos AD, Tzeis S, Paizis I, Moraitis P, Varonos D, Cokkinos DV. Ischaemic preconditioning induced protection is preserved in thyroxine treated rat hearts despite attenuation of the PKC/p38 MAP Kinase pathway. *J Mol Cell Cardiol* 2001;33(6):A89
 37. Pantos C, Malliopoulou V, Karamanoli E, Tzeis S, Cokkinos DD, Mourouzis I, Varonos D, Cokkinos D. Differential HSP70 mRNA expression induced by preconditioning in aortic constriction and thyroxine induced cardiac hypertrophy. *French Cardiac Society* 2001, vol of abstracts, P403.
 38. Pantos C, Karamanoli E, Malliopoulou V, Mourouzis I, Tzeis S, Cokkinos DD, Varonos D, Cokkinos DV. Differential HSP70 mRNA expression induced by global ischaemia in acute and chronic hyperthyroidism in the rat heart. *French Cardiac Society* 2001, vol of abstracts, P402 1st AWARD
 39. Malliopoulou V, Pantos C, Tzeis S, Mourouzis I, Cokkinos DD, Steimberg N, Carageorgiou H, Varonos D, Cokkinos DV. Ischaemia augments but ischaemic preconditioning attenuates HSP70 mRNA induction in the hyperthyroid rat heart. *Eur Heart J* 2000; 21:P3637

40. Cokkinos DD, Pantos C, Batali E, Kastelanos E, Mourouzis I, Asimacopoulos P, Carageorgiou H, Varonos D, Cokkinos DV. Thyroxine administration prevents the deleterious effect of dobutamine on postischaemic function. Eur Heart J 1999; 30:P543 (1.3)

ΕΡΕΥΝΗΤΙΚΟ- ΣΥΓΓΡΑΦΙΚΟ ΕΡΓΟ (Συνολικός αριθμός, συντελεστής απήχησης βιβλιογραφικές αναφορές)

Ξενόγλωσσες δημοσιεύσεις σε διεθνή περιοδικά (peer review) (σύνολο): **86**

Πρωτότυπη έρευνα: **72** Ανασκοπήσεις: **12**

Γράμματα σύνταξης & commentaries σε διεθνή περιοδικά (σύνολο): **2**

Ξενόγλωσσες ανακοινώσεις δημοσιευμένες σε περιοδικά: **40**

Κεφάλαια σε βιβλία: 1 (Ελληνικά) + **2** (διεθνή)

ΣΥΝΤΕΛΕΣΤΗΣ ΑΠΗΧΗΣΗΣ (IF²⁰¹⁴) συνολικός: **233.9** μέσος: **2.78**

H-INDEX **26** (SCOPUS), **30** (SCHOLAR)

ΑΝΑΦΟΡΕΣ: **1616** (SCOPUS), **2200** (SCHOLAR)

1^{ος} συγγραφέας: **10**, 2^{ος} συγγραφέας: **30**, τελευταίος συγγραφέας: **5**

ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΔΡΑΣΤΗΡΙΟΤΗΤΕΣ

Συμμετοχή σε διεθνή συνέδρια/επιστημονικές συναντήσεις ως ομιλητής

1. *“Thyroid hormone and cardiopreservation in cardiac surgery and organ transplantation”* International Symposium on Translating thyroid hormone action in non-thyroid care setting: Current options and future perspectives. June 2015, Delphi, Greece
2. *“Amiodarone and Dronedarone interaction with thyroid hormone: Clinical implications”* International Symposium on Translating thyroid hormone action in non-thyroid care setting: Current options and future perspectives. June 2015, Delphi, Greece
3. *«Ο αιμοκαθαιρόμενος ασθενής από την πλευρά του καρδιολόγου. Φάρμακα: τι πρέπει να προσέχουμε»* 7ο Διεθνές Συμπόσιο «Καρδιαγγειακές Παθήσεις και Νεφρική Δυσλειτουργία 2015», 16-17 Ιανουαρίου 2015, Αθήνα, Ίδρυμα Ευγενίδου
4. *“Biomedical data journal and Opensciencelink project overview”* Special meeting at Heidelberg with the Metadata director and R&D vice chairman of SpringerOpen, 22 June 2014

5. “*TR α1 receptor : a molecular switch for conversion of pathologic to physiologic growth*” International Symposium of Oxidative Stress and Cardiovascular Disease, Porto Alegre, Brasil, **2013**.
6. “*The role of thyroid hormone in ischemia-reperfusion injury*”, Postgraduate Courses in Department of Physiology, University of Porto Alegre, Brasil, **2013**.
7. «*Οξειδωτικό στρές και ισχαιμία*», Ομάδες Εργασίας Ελληνικής Καρδιολογικής Εταιρείας, Θεσσαλονίκη, **2006**.
8. «*Θυρεοειδική ορμόνη και καρδιοπροστασία*», Ομάδες Εργασίας Ελληνικής Καρδιολογικής Εταιρείας, Θεσσαλονίκη, **2005**.

Οργάνωση συνεδρίων /επιστημονικών συναντήσεων

2015- Οργάνωση της διεθνούς ημερίδας «*Translating thyroid hormone action in non-thyroid care setting: Current options and future perspectives*» σε συνεργασία με την European Thyroid Association (Δελφοί)

2008- Οργάνωση του Ευρωπαϊκού Συνεδρίου της International Society of Heart Research (Αθήνα)

2002-2009 Οργάνωση του ‘Athens Exchange of Cardiovascular Research Ideas’ (Workshop): Ετήσιες διεθνείς επιστημονικές συναντήσεις υπό την αιγίδα της International Society for Heart Research, του Εργαστηρίου Φαρμακολογίας και της Ελληνικής Καρδιολογικής Εταιρείας

Συντακτικό/ Συμβουλευτικό έργο (κριτής σε επιστημονικά περιοδικά, κριτής ερευνητικών προγραμμάτων)

Συντάκτης σε Περιοδικά

Associate Editor of the “Biomedical Data Journal”

Κριτής στα επιστημονικά περιοδικά:

Journal of Thyroid Research, Oxidative Medicine and Cellular Longevity, Heart Failure Reviews, PLOS one, Molecular Medicine, Vascular Pharmacology, International Journal of Endocrinology

Μέλος Επιστημονικών Εταιρειών

Ελληνική Καρδιολογική Εταιρεία (ΕΚΕ)
Ομάδα βασικής έρευνας της ΕΚΕ
International Society of Heart Research-European Section

Διεθνείς Επιστημονικές συνεργασίες

- Gilead Sciences , Fremont, Silicon Valley , USA (A. DHALLA, L. BELARDINELI)
- CNR, Pisa, Italy (PROF. G. IERVASI)
- School of Forensic and Investigative Science, University of Central Lancashire, Preston, UK (PROF. J. SINGH)
- King's College London, UK (PROF. M. MARBER)
- Inserm Institute, Paris, France, (PROF. B. SWYNGHEDAUW)
- School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, UK (PROF. R. LEA)
- Quidd, Rouen, France (DR HEIDI LIGERET)
- Department of Human Anatomy and Cell Science and Physiology, St. Boniface Research Centre, Institute of Cardiovascular Sciences, University of Manitoba, Winnipeg, Canada (PROF. E. KARDAMI)
- SANOFI-AVENTIS, FRANCE (DR. D. NISATO)
- SERVIER, FRANCE (DR A. Bescond-Jacquet)
- MENARINI INTERNATIONAL

